Preface
Targeted therapy and non-small cell lung cancer: a new era!
Translational Cancer Research
2019;
8
(Suppl 1)
:S1-S2
.
(19 January 2019)
Original Article
Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform
Translational Cancer Research
2019;
8
(Suppl 1)
:S3-S15
.
(19 January 2019)
Listening understanding and acting (lung): focus on communicational issue in thoracic oncology
Translational Cancer Research
2019;
8
(Suppl 1)
:S16-S22
.
(19 January 2019)
Review Article
EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
Translational Cancer Research
2019;
8
(Suppl 1)
:S23-S47
.
(19 January 2019)
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
Translational Cancer Research
2019;
8
(Suppl 1)
:S48-S54
.
(19 January 2019)
Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
Translational Cancer Research
2019;
8
(Suppl 1)
:S55-S63
.
(19 January 2019)
Case Report
EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: a case report and literature review
Translational Cancer Research
2019;
8
(Suppl 1)
:S64-S69
.
(19 January 2019)
Editorial
Immunotherapy as a targeted therapy in non-small cell lung cancer
Translational Cancer Research
2019;
8
(Suppl 1)
:S70-S75
.
(19 January 2019)
Perspective
EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy
Translational Cancer Research
2019;
8
(Suppl 1)
:S76-S78
.
(19 January 2019)
Disclosure:
The supplement “Targeted Therapy and Non-Small Cell Lung Cancer: A New Era?” was commissioned by the editorial office, Translational Cancer Research without any sponsorship or funding. Umberto Malapelle and Christian Rolfo served as the unpaid Guest Editors for the supplement.
